Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives

Background: Tuberculosis (TB) remains a global health challenge, necessitating the discovery of novel anti-tubercular agents. The N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II) scaffold has shown potential in developing effective drug candidates. Objective: This study...

Full description

Saved in:
Bibliographic Details
Main Authors: Mahesh Agasa Ramu, Somashekhar Metri, Trupti A Hunnura, Koushallya Patil, Hanamant B Sannakki
Format: Article
Language:English
Published: Creative Pharma Assent 2025-02-01
Series:Journal of Applied Pharmaceutical Research
Subjects:
Online Access:https://japtronline.com/index.php/joapr/article/view/722
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850240959344803840
author Mahesh Agasa Ramu
Somashekhar Metri
Trupti A Hunnura
Koushallya Patil
Hanamant B Sannakki
author_facet Mahesh Agasa Ramu
Somashekhar Metri
Trupti A Hunnura
Koushallya Patil
Hanamant B Sannakki
author_sort Mahesh Agasa Ramu
collection DOAJ
description Background: Tuberculosis (TB) remains a global health challenge, necessitating the discovery of novel anti-tubercular agents. The N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II) scaffold has shown potential in developing effective drug candidates. Objective: This study aimed to design and evaluate 50 derivatives of HSM-II for their anti-tubercular activity, focusing on compounds demonstrating strong interactions with the protein PKS13 (PDB ID: 5v3y). Methods: A series of derivatives was synthesized, starting with the reaction of 8-bromo-3,4-dihydro-2H-1-benzopyran-6-amine and phenyl carbamic acid, yielding six new benzopyran derivatives. These were further treated with various aromatic halides to produce the HSM-II derivatives. Molecular docking studies were performed to identify compounds with high binding affinity to PKS13. Promising candidates (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) were selected for biological evaluation. Anti-tubercular activity was assessed in vitro using the Alamar Blue Susceptibility Test (MABA) against Mycobacterium tuberculosis H37Rv and H37Ra strains. Results: Docking studies revealed high binding scores for the selected compounds, indicating strong interactions with the target protein. In vitro evaluations demonstrated significant anti-tubercular activity for the majority of synthesized derivatives. The pharmacologic profile of the compounds suggests potential as lead candidates for further optimization. Conclusion: This study presents the design, synthesis, and biological evaluation of 50 diverse derivatives of N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II). Six derivatives (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) demonstrated high binding affinities with PKS13 (PDB ID: 5v3y), with scores reaching -11.4 kcal/mol, and potent in vitro anti-tubercular activity, as assessed using the Alamar Blue Susceptibility Assay (MABA). Prominent derivatives exhibited MIC values significantly lower than those of standard drugs like rifampicin.
format Article
id doaj-art-caec5588d4a8436c97625f4de3c4c6a0
institution OA Journals
issn 2348-0335
language English
publishDate 2025-02-01
publisher Creative Pharma Assent
record_format Article
series Journal of Applied Pharmaceutical Research
spelling doaj-art-caec5588d4a8436c97625f4de3c4c6a02025-08-20T02:00:43ZengCreative Pharma AssentJournal of Applied Pharmaceutical Research2348-03352025-02-01131869410.69857/joapr.v13i1.722723Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivativesMahesh Agasa Ramu0https://orcid.org/0000-0003-4073-9021Somashekhar Metri1Trupti A Hunnura2Koushallya Patil3Hanamant B Sannakki4Department of Pharmaceutical Chemistry, The Oxford College of Pharmacy, Bengaluru, Karnataka, IndiaDepartment of Pharmaceutical Chemistry, BLDEA’S SSM College of Pharmacy and Research Centre, Vijayapura 586103, Karnataka, IndiaDepartment of Pharmaceutical Chemistry, BLDEA’S SSM College of Pharmacy and Research Centre, Vijayapura 586103, Karnataka, IndiaDepartment of Pharmaceutical Chemistry, BLDEA’S SSM College of Pharmacy and Research Centre, Vijayapura 586103, Karnataka, IndiaDepartment of Pharmaceutical Chemistry, BLDEA’S SSM College of Pharmacy and Research Centre, Vijayapura 586103, Karnataka, IndiaBackground: Tuberculosis (TB) remains a global health challenge, necessitating the discovery of novel anti-tubercular agents. The N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II) scaffold has shown potential in developing effective drug candidates. Objective: This study aimed to design and evaluate 50 derivatives of HSM-II for their anti-tubercular activity, focusing on compounds demonstrating strong interactions with the protein PKS13 (PDB ID: 5v3y). Methods: A series of derivatives was synthesized, starting with the reaction of 8-bromo-3,4-dihydro-2H-1-benzopyran-6-amine and phenyl carbamic acid, yielding six new benzopyran derivatives. These were further treated with various aromatic halides to produce the HSM-II derivatives. Molecular docking studies were performed to identify compounds with high binding affinity to PKS13. Promising candidates (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) were selected for biological evaluation. Anti-tubercular activity was assessed in vitro using the Alamar Blue Susceptibility Test (MABA) against Mycobacterium tuberculosis H37Rv and H37Ra strains. Results: Docking studies revealed high binding scores for the selected compounds, indicating strong interactions with the target protein. In vitro evaluations demonstrated significant anti-tubercular activity for the majority of synthesized derivatives. The pharmacologic profile of the compounds suggests potential as lead candidates for further optimization. Conclusion: This study presents the design, synthesis, and biological evaluation of 50 diverse derivatives of N-(8-hydrazinyl-3,4-dihydro-2H-1-benzopyran-6-yl)-N'-phenyl urea (HSM-II). Six derivatives (HSM-II-3, HSM-II-13, HSM-II-27, HSM-II-33, HSM-II-42, and HSM-II-49) demonstrated high binding affinities with PKS13 (PDB ID: 5v3y), with scores reaching -11.4 kcal/mol, and potent in vitro anti-tubercular activity, as assessed using the Alamar Blue Susceptibility Assay (MABA). Prominent derivatives exhibited MIC values significantly lower than those of standard drugs like rifampicin.https://japtronline.com/index.php/joapr/article/view/722anti-tubercular compoundspks13 (pdb id: 5v3y)molecular dockingbenzopyran derivativesalamar blue susceptibility assay (maba)
spellingShingle Mahesh Agasa Ramu
Somashekhar Metri
Trupti A Hunnura
Koushallya Patil
Hanamant B Sannakki
Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
Journal of Applied Pharmaceutical Research
anti-tubercular compounds
pks13 (pdb id: 5v3y)
molecular docking
benzopyran derivatives
alamar blue susceptibility assay (maba)
title Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
title_full Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
title_fullStr Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
title_full_unstemmed Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
title_short Investigation of molecular design, synthesis, and biological assessment of new benzopyran derivatives
title_sort investigation of molecular design synthesis and biological assessment of new benzopyran derivatives
topic anti-tubercular compounds
pks13 (pdb id: 5v3y)
molecular docking
benzopyran derivatives
alamar blue susceptibility assay (maba)
url https://japtronline.com/index.php/joapr/article/view/722
work_keys_str_mv AT maheshagasaramu investigationofmoleculardesignsynthesisandbiologicalassessmentofnewbenzopyranderivatives
AT somashekharmetri investigationofmoleculardesignsynthesisandbiologicalassessmentofnewbenzopyranderivatives
AT truptiahunnura investigationofmoleculardesignsynthesisandbiologicalassessmentofnewbenzopyranderivatives
AT koushallyapatil investigationofmoleculardesignsynthesisandbiologicalassessmentofnewbenzopyranderivatives
AT hanamantbsannakki investigationofmoleculardesignsynthesisandbiologicalassessmentofnewbenzopyranderivatives